Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Xylem, Inc. (XYL) Price & Performance

BridgeBio Pharma IncTrade
Xylem, Inc.Trade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Xylem, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Xylem, Inc. trades at $123.19 (market cap $28.76B). The key difference: Xylem, Inc. is the larger of the two by market cap, and Xylem, Inc. pays a 1.4% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

BBIOXYL
Market Cap
$16.36B$28.76B
Sector
HealthIndustrials
52-Week High
$90.17$152.95
52-Week Low
$47.29$106.34
Enterprise Value
$18.14B$30.54B
Dividend Yield
1.4%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Xylem, Inc.

Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.

Read more on XYL